Home > News

Creat takeover of Biotest closed. Transfer for tendered shares completed.

Creat takeover of Biotest closed

02/ 1/2018

Creat takeover of Biotest closed

  • Transfer of tendered shares completed
  • Majority shareholding (approx. 90% of Biotest AG’s ordinary shares and voting share capital) of Creat in Biotest

Dreieich, 31 January 2018. On 19 January 2018 Biotest AG disclosed that the last remaining condition has been met for the takeover offer by Tiancheng (Germany) Pharmaceutical Holdings AG, the acquisition company of the Creat Group Corporation. Thus the  unsolicited takeover  offer  announced  on 18 May 2017 for the shares of Biotest AG became effective and could be settled.

The offer by Tiancheng (Germany) Pharmaceutical Holdings AG and payment of the purchase price to the custodial bank of the accepting Biotest shareholders was settled promptly and, as described in section 13.5 of the offer document.

Tiancheng (Germany) Pharmaceutical Holdings AG, an indirect controlled subsidiary of CREAT, a company organized and existing under the laws of the People’s Republic of China, hereby holds a majority interest (approx. 90% of Biotest AG’s ordinary shares and voting share capital) in Biotest AG.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised
primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and
systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

IR contact

Dr. Monika Buttkereit Phone: +49-6103-801-4406


PR contact

Dirk Neumüller

Phone: +49-6103-801-269


Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate


This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.